These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23137154)

  • 1. Olanzapine in schizophrenia and affective disorders.
    Undurraga J; Vieta E; Tohen M; Colom F
    Drug Saf; 2012 Dec; 35(12):1185-6; author reply 1186. PubMed ID: 23137154
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.
    Baldessarini RJ
    Drug Saf; 2012 Dec; 35(12):1183; author reply 1183-4. PubMed ID: 23137152
    [No Abstract]   [Full Text] [Related]  

  • 3. Olanzapine: a critical review of recent literature.
    Buckley PF
    Expert Opin Pharmacother; 2005 Oct; 6(12):2077-89. PubMed ID: 16197360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.
    Moteshafi H; Zhornitsky S; Brunelle S; Stip E
    Drug Saf; 2012 Oct; 35(10):819-36. PubMed ID: 22967188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose ziprasidone in treatment-resistant schizophrenia and affective spectrum disorders: a case series.
    Deutschman DA; Deutschman DH
    J Clin Psychopharmacol; 2007 Oct; 27(5):513-4. PubMed ID: 17873687
    [No Abstract]   [Full Text] [Related]  

  • 6. Dermatological side effects of olanzapine.
    Varghese ST; Balhara YP; Shyamsunder S; Mondal A
    Indian J Med Sci; 2005 Jul; 59(7):320-1. PubMed ID: 16062020
    [No Abstract]   [Full Text] [Related]  

  • 7. The incidence of hyperglycemia in patients treated with olanzapine.
    Misawa F; Miyaji S; Fuji Y; Miyata R; Obi K; Koshiishi F; Shimada H; Fukuda M; Koizumi T
    J Clin Psychiatry; 2004 Mar; 65(3):443-4. PubMed ID: 15096088
    [No Abstract]   [Full Text] [Related]  

  • 8. Is there a real difference in severity of tardive dyskinesia between risperidone and olanzapine?
    Suzuki T; Takeuchi H; Watanabe K
    J Clin Psychiatry; 2010 Nov; 71(11):1553-4; author reply 1554. PubMed ID: 21114953
    [No Abstract]   [Full Text] [Related]  

  • 9. Olanzapine-induced oculogyric crisis in a patient with schizophrenia.
    Chakraborty R; Chatterjee A; Chaudhury S
    Indian J Med Sci; 2008 Jun; 62(6):238-9. PubMed ID: 18603742
    [No Abstract]   [Full Text] [Related]  

  • 10. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable.
    Rosa F; Schreiner A; Thomas P; Sherif T
    Clin Drug Investig; 2012 Apr; 32(4):267-79. PubMed ID: 22339430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report.
    Markham-Abedi C; de Leon J
    J Clin Psychiatry; 2006 Sep; 67(9):1473-4. PubMed ID: 17017841
    [No Abstract]   [Full Text] [Related]  

  • 12. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: an empirical evaluation of olanzapine, risperidone, and quetiapine.
    Byerly MJ; Nakonezny PA; Bettcher BM; Carmody T; Fisher R; Rush AJ
    Schizophr Res; 2006 Sep; 86(1-3):244-50. PubMed ID: 16730951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine induced de-novo obsessive compulsive disorder in a patient with schizophrenia.
    Kulkarni G; Narayanaswamy JC; Math SB
    Indian J Pharmacol; 2012; 44(5):649-50. PubMed ID: 23112432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Subjective and objective evaluation of olanzapine treatment in schizophrenia].
    Jarema M; Murawiec S; Tafliński T
    Psychiatr Pol; 2004; 38(5):895-909. PubMed ID: 15523935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurologic soft signs and olanzapine treatment in chronic schizophrenia.
    Sevincok L; Topaloglu B; Kiyilioglu N
    J Clin Psychopharmacol; 2004 Oct; 24(5):571-2. PubMed ID: 15349026
    [No Abstract]   [Full Text] [Related]  

  • 16. [Tardive dyskinesia in patients with schizophrenia treated with olanzapine - results from a 20-month, prospective, open study under naturalistic conditions].
    Szafrański T
    Psychiatr Pol; 2014; 48(6):1155-65. PubMed ID: 25717485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comments on "Weight gain management in patients with schizophrenia during treatment with olanzapine in association with nizatidine".
    Reis de Sá A; Elkis H
    Braz J Psychiatry; 2007 Mar; 29(1):90; author reply 91. PubMed ID: 17435940
    [No Abstract]   [Full Text] [Related]  

  • 20. Bradyarrhythmic shock associated with olanzapine.
    Chen CC; Tsai JH; Yang P; Chung W
    Aust N Z J Psychiatry; 2007 Jan; 41(1):89. PubMed ID: 17464686
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.